Breaking News

Royalty Pharma and Jefferies Invest $111M in ApiJect

Investment to support development and deployment of ApiJect’s High-Volume Manufacturing platform for single-dose prefilled injection devices.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation in the fill and finish and delivery of injectable vaccines and medicines, completed a $111 million private round of investment led by Royalty Pharma and Jefferies Financial Group. This investment values ApiJect at approximately $300 million.    The funds will be used for continued development of ApiJect’s Blow-Fill-Seal (BFS) plastic prefilled injection system, to deploy its eq...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters